HHS launches $500m universal vaccines initiative
The US Department of Health and Human Services (HHS) has launched a $500m initiative to accelerate the development of universal…
02 May 2025
FDA awards RMAT status to 4DMT diabetic macular oedema therapy
4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for 4D-150 for diabetic macular oedema. The therapy is tailored…
02 May 2025
Repare signs out-licensing deal with DCx Biotherapeutics
Repare Therapeutics has entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP). Repare will obtain $4m in upfront and near-term payments from…
01 May 2025
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
Biogen has unveiled Q1 2025 revenues above estimates, spurred by strong sales of rare disease assets amid a sales dropoff from its multiple sclerosis business. Quarterly revenues for the…
01 May 2025
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
Eli Lilly has reported $12.73bn in Q1 2025 revenue, a 45% increase from the prior year, driven largely by demand for its diabetes and obesity drugs, Mounjaro (tirzepatide) and Zepbound…
01 May 2025
New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in South London, UK. Insurance company Aviva’s investment arm and property…
01 May 2025
Dimerix and Amicus to commercialise DMX-200 in US
Australian biopharmaceutical company Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug candidate DMX-200. The drug will be marketed for all…